Brokerages Set Albireo Pharma Inc (NASDAQ:ALBO) Target Price at $60.33

Albireo Pharma Inc (NASDAQ:ALBO) has been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $60.33.

ALBO has been the subject of several research reports. William Blair reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Monday, July 15th. BidaskClub raised shares of Albireo Pharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 21st. ValuEngine upgraded Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. HC Wainwright restated a “buy” rating and issued a $62.00 price target on shares of Albireo Pharma in a research report on Sunday, August 11th. Finally, Zacks Investment Research cut Albireo Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th.

Shares of Albireo Pharma stock traded up $0.38 during trading hours on Thursday, reaching $25.70. 25,654 shares of the company’s stock were exchanged, compared to its average volume of 49,851. The business has a fifty day moving average of $24.87 and a two-hundred day moving average of $30.24. The company has a market capitalization of $320.43 million, a P/E ratio of -6.52 and a beta of 1.53. Albireo Pharma has a 1 year low of $19.10 and a 1 year high of $38.69.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.44) by $0.09. The firm had revenue of $1.25 million for the quarter, compared to the consensus estimate of $1.11 million. Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.74%. As a group, research analysts anticipate that Albireo Pharma will post -5.91 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in ALBO. Bank of America Corp DE grew its holdings in shares of Albireo Pharma by 87.6% in the fourth quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 3,020 shares during the period. Alps Advisors Inc. boosted its holdings in Albireo Pharma by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 28,912 shares of the biopharmaceutical company’s stock valued at $931,000 after purchasing an additional 1,253 shares during the last quarter. Federated Investors Inc. PA boosted its holdings in Albireo Pharma by 22.8% in the 1st quarter. Federated Investors Inc. PA now owns 719,595 shares of the biopharmaceutical company’s stock valued at $23,178,000 after purchasing an additional 133,449 shares during the last quarter. Private Advisors LLC grew its stake in shares of Albireo Pharma by 3.4% in the 1st quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 506 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Albireo Pharma in the 1st quarter valued at approximately $816,000. 73.02% of the stock is currently owned by hedge funds and other institutional investors.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Further Reading: How does the Beige Book influence monetary policy?

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.